Lurasidona no Manejo do Transtorno do Espectro Autista: Uma Revisão

Abstract

OBJECTIVE: To demonstrate that lurasidone can be an alternative for adolescents with Autistic Spectrum Disorder (ASD), especially if the patient has a history of adverse metabolic effects and / or ineffectiveness or intolerance to the use of aripiprazole or risperidone. METHODS: Systematic review of articles from the PubMed platform, with only articles in Portuguese and English being selected, with no period limitation. Inclusion criteria for the study: studies that address the treatment of ASD; studies that address treatment focusing on the use of lurasidone; works that bring clear methodology. RESULTS: Lurasidone has shown promise, given its low profile of adverse effects, such as lower weight gain, hyperlipidemia, hyperglycemia and insulin resistance. In addition to the potential benefits of lurasidone for the treatment of irritability in children with ASD, there may also be a potential antidepressant effect, which may influence the symptom profile. It is currently approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia in adolescents from the age of thirteen and on monotherapy for bipolar depression from the age of ten. However, there are studies of tolerance in children and adolescents from the age of six with doses <120 mg / day. CONCLUSION: Given the risk of long-term adverse metabolic effects of most atypical antipsychotics, lurasidone can serve as an alternative. However, to date, no evidence has been found consistent with the use of lurasidone for patients with ASD who exhibit irritability, aggressiveness and impulsivity as associated symptoms.